Sökning: (WFRF:(Perfekt Roland)) > FDG PET studies dur...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05654naa a2200589 4500 | |
001 | oai:lup.lub.lu.se:5cb8efc7-dd78-4119-8426-fbcad0dbd082 | |
003 | SwePub | |
008 | 160401s2002 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/1060262 URI |
024 | 7 | a https://doi.org/10.1002/hed.100372 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Brun, Evau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-ebr |
245 | 1 0 | a FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma. |
264 | c 2002-01-02 | |
264 | 1 | b Wiley,c 2002 |
520 | a BACKGROUND: Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC. METHODS: Between 1993 and 1999 47 patients underwent PET before (PET(1)) and after (PET(2)) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow-up time was 3.3 years. RESULTS: Low and high MR FDG at PET(2), with median value as cutoff, was associated with complete remission in 96% and 62% (p =.007), with 5-year overall survival in 72% and 35% (p =.0042) and with local control in 96% and 55% (p =.002), respectively. CONCLUSIONS: FDG PET in the early phase of treatment of HNSCC is associated with tumor response, survival, and local control. Copyright 2002 John Wiley & Sons, Inc. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Oto-rhino-laryngologi0 (SwePub)302182 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Otorhinolaryngology0 (SwePub)302182 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng |
653 | a Fludeoxyglucose F 18/*diagnostic use/pharmacokinetics | |
653 | a Female | |
653 | a Head and Neck Neoplasms/mortality/*radionuclide imaging/*therapy | |
653 | a Human | |
653 | a Male | |
653 | a Middle Age | |
653 | a Predictive Value of Tests | |
653 | a Reproducibility of Results | |
653 | a Radiopharmaceuticals/*diagnostic use/pharmacokinetics | |
653 | a Squamous Cell/mortality/*radionuclide imaging/*therapy | |
653 | a Carcinoma | |
653 | a 80 and over | |
653 | a Aged | |
700 | 1 | a Kjellén, Elisabethu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-ekj |
700 | 1 | a Tennvall, Janu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-jte |
700 | 1 | a Ohlsson, Tomas Gu Lund University,Lunds universitet,Medicinsk strålningsfysik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical Radiation Physics, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)rafy-toh |
700 | 1 | a Sandell, Andersu Lund University,Lunds universitet,Medicinsk strålningsfysik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical Radiation Physics, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)nucl-asa |
700 | 1 | a Perfekt, Rolandu Lund University,Lunds universitet,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)endo-rpe |
700 | 1 | a Wennerberg, Johanu Lund University,Lunds universitet,Öron-, näs- och halssjukdomar, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Otorhinolaryngology (Lund),Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onh-jwe |
700 | 1 | a Strand, Sven-Eriku Lund University,Lunds universitet,Medicinsk strålningsfysik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical Radiation Physics, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)rafy-ses |
710 | 2 | a Bröstcancer-genetikb Sektion I4 org |
773 | 0 | t Head and Neckd : Wileyg 24:2, s. 127-135q 24:2<127-135x 1043-3074 |
856 | 4 | u http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11891942&dopt=Abstracty FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1002/hed.10037y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/106026 |
856 | 4 8 | u https://doi.org/10.1002/hed.10037 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.